Cargando…

Drug2ways: Reasoning over causal paths in biological networks for drug discovery

Elucidating the causal mechanisms responsible for disease can reveal potential therapeutic targets for pharmacological intervention and, accordingly, guide drug repositioning and discovery. In essence, the topology of a network can reveal the impact a drug candidate may have on a given biological st...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivas-Barragan, Daniel, Mubeen, Sarah, Guim Bernat, Francesc, Hofmann-Apitius, Martin, Domingo-Fernández, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735677/
https://www.ncbi.nlm.nih.gov/pubmed/33264280
http://dx.doi.org/10.1371/journal.pcbi.1008464
_version_ 1783622682969899008
author Rivas-Barragan, Daniel
Mubeen, Sarah
Guim Bernat, Francesc
Hofmann-Apitius, Martin
Domingo-Fernández, Daniel
author_facet Rivas-Barragan, Daniel
Mubeen, Sarah
Guim Bernat, Francesc
Hofmann-Apitius, Martin
Domingo-Fernández, Daniel
author_sort Rivas-Barragan, Daniel
collection PubMed
description Elucidating the causal mechanisms responsible for disease can reveal potential therapeutic targets for pharmacological intervention and, accordingly, guide drug repositioning and discovery. In essence, the topology of a network can reveal the impact a drug candidate may have on a given biological state, leading the way for enhanced disease characterization and the design of advanced therapies. Network-based approaches, in particular, are highly suited for these purposes as they hold the capacity to identify the molecular mechanisms underlying disease. Here, we present drug2ways, a novel methodology that leverages multimodal causal networks for predicting drug candidates. Drug2ways implements an efficient algorithm which reasons over causal paths in large-scale biological networks to propose drug candidates for a given disease. We validate our approach using clinical trial information and demonstrate how drug2ways can be used for multiple applications to identify: i) single-target drug candidates, ii) candidates with polypharmacological properties that can optimize multiple targets, and iii) candidates for combination therapy. Finally, we make drug2ways available to the scientific community as a Python package that enables conducting these applications on multiple standard network formats.
format Online
Article
Text
id pubmed-7735677
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-77356772020-12-22 Drug2ways: Reasoning over causal paths in biological networks for drug discovery Rivas-Barragan, Daniel Mubeen, Sarah Guim Bernat, Francesc Hofmann-Apitius, Martin Domingo-Fernández, Daniel PLoS Comput Biol Research Article Elucidating the causal mechanisms responsible for disease can reveal potential therapeutic targets for pharmacological intervention and, accordingly, guide drug repositioning and discovery. In essence, the topology of a network can reveal the impact a drug candidate may have on a given biological state, leading the way for enhanced disease characterization and the design of advanced therapies. Network-based approaches, in particular, are highly suited for these purposes as they hold the capacity to identify the molecular mechanisms underlying disease. Here, we present drug2ways, a novel methodology that leverages multimodal causal networks for predicting drug candidates. Drug2ways implements an efficient algorithm which reasons over causal paths in large-scale biological networks to propose drug candidates for a given disease. We validate our approach using clinical trial information and demonstrate how drug2ways can be used for multiple applications to identify: i) single-target drug candidates, ii) candidates with polypharmacological properties that can optimize multiple targets, and iii) candidates for combination therapy. Finally, we make drug2ways available to the scientific community as a Python package that enables conducting these applications on multiple standard network formats. Public Library of Science 2020-12-02 /pmc/articles/PMC7735677/ /pubmed/33264280 http://dx.doi.org/10.1371/journal.pcbi.1008464 Text en © 2020 Rivas-Barragan et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rivas-Barragan, Daniel
Mubeen, Sarah
Guim Bernat, Francesc
Hofmann-Apitius, Martin
Domingo-Fernández, Daniel
Drug2ways: Reasoning over causal paths in biological networks for drug discovery
title Drug2ways: Reasoning over causal paths in biological networks for drug discovery
title_full Drug2ways: Reasoning over causal paths in biological networks for drug discovery
title_fullStr Drug2ways: Reasoning over causal paths in biological networks for drug discovery
title_full_unstemmed Drug2ways: Reasoning over causal paths in biological networks for drug discovery
title_short Drug2ways: Reasoning over causal paths in biological networks for drug discovery
title_sort drug2ways: reasoning over causal paths in biological networks for drug discovery
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735677/
https://www.ncbi.nlm.nih.gov/pubmed/33264280
http://dx.doi.org/10.1371/journal.pcbi.1008464
work_keys_str_mv AT rivasbarragandaniel drug2waysreasoningovercausalpathsinbiologicalnetworksfordrugdiscovery
AT mubeensarah drug2waysreasoningovercausalpathsinbiologicalnetworksfordrugdiscovery
AT guimbernatfrancesc drug2waysreasoningovercausalpathsinbiologicalnetworksfordrugdiscovery
AT hofmannapitiusmartin drug2waysreasoningovercausalpathsinbiologicalnetworksfordrugdiscovery
AT domingofernandezdaniel drug2waysreasoningovercausalpathsinbiologicalnetworksfordrugdiscovery